Astrocytoma, IDH-Mutant, Grade 2 — Trials

Astrocytoma, IDH-Mutant, Grade 2 — Trials · CancerIndex

Clinical trials

Registered studies

8 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06047379	Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis	recruiting	Phase 1 / Phase 2	134	Neonc Technologies, Inc.INDUSTRY	1	Sep 24, 2026	clinicaltrials
NCT03528642	Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma	active not recruiting	Phase 1	23	National Cancer Institute (NCI)NIH	1	Sep 22, 2026	clinicaltrials
NCT06860594	Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma	recruiting	Phase 1	30	National Cancer Institute (NCI)NIH	1	Sep 2, 2026	clinicaltrials

Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials